Funded Biotechnology Startups in Melbourne
Disclosed round sizes here cluster tightly below $50M, with one clear outlier: Telix Pharmaceuticals’ $600M round dated 2026-04-14.
Disclosed round sizes here cluster tightly below $50M, with one clear outlier: Telix Pharmaceuticals’ $600M round dated 2026-04-14. The next-largest disclosed amounts are $100M (Propanc, 2025-10-15) and $50M (Mesoblast, 2026-06-24), putting Telix’s disclosed figure well above the rest of the list’s disclosed amounts.
Geographically, every disclosed entry in this set is tied to Melbourne, Victoria, or “Melbourne” in a single listing, indicating a strong city concentration rather than multiple metro areas. Stage and classification also skew toward early-to-mid risk: Seed appears in 3 of 13 rows (Fluent $2M on 2026-06-29; Nutromics $7M on 2023-06-08; Tiny Bright Things $2M on 2022-11-03), while “Series Unknown” is present in 4 of 13 rows (Mesoblast, Paradigm Biopharmaceuticals, Propanc, and Telix). The 13 rounds span 2022-11-03 through 2026-06-29.
Most recent rounds
13 shownRelated listings
Frequently asked
What is the largest disclosed round in this Melbourne biotechnology list, and how does it compare to the rest of the disclosed amounts?
Telix Pharmaceuticals’ $600M round on 2026-04-14 is an outlier relative to the next-highest disclosed amounts: Propanc’s $100M (2025-10-15) and Mesoblast’s $50M (2026-06-24). Aside from those, the remaining disclosed rounds mostly sit below $22M (e.g., Ena Respiratory $22M on 2025-10-22; RAGE Biotech $19M on 2025-11-10).
Are there any temporal clusters among these 13 most recent rounds?
Yes. Four of the 13 rounds fall between 2026-04-14 and 2026-06-29: Telix Pharmaceuticals ($600M, 2026-04-14), Paradigm Biopharmaceuticals ($10M, 2026-04-27), Mesoblast ($50M, 2026-06-24), and Fluent ($2M, 2026-06-29). A separate recent cluster appears in late 2025, including Ena Respiratory ($22M, 2025-10-22), Propanc ($100M, 2025-10-15), and RAGE Biotech ($19M, 2025-11-10).
How concentrated is the geography within this list—does it spread beyond Melbourne?
All 13 entries are located in Melbourne-related labels: either “Melbourne, Victoria, Australia” (e.g., Fluent 2026-06-29; Telix Pharmaceuticals 2026-04-14) or “Melbourne, Victoria, Australia” for each listed company, including RAGE Biotech which is listed as “Melbourne, Australia.” There are no other city geographies shown in the rows.
What stage mix dominates the disclosed entries here?
Seed rounds account for 3 of 13 rows: Fluent ($2M, 2026-06-29), Nutromics ($7M, 2023-06-08), and Tiny Bright Things ($2M, 2022-11-03). “Series Unknown” is also common, appearing in 4 of 13 rows (Mesoblast, Paradigm Biopharmaceuticals, Propanc, Telix), while Series B appears in 4 of 13 rows (Ena Respiratory $22M on 2025-10-22; Kinoxis Therapeutics $10M on 2024-08-12; Aravax $20M on 2022-12-20; plus one more Series B entry shown as Ena and Kinoxis and Aravax total).
Which classification entries look like data-quality or size outliers to verify?
Two entries are outside the disclosed-amount pattern: Cell Bauhaus (Pre-Seed, 2024-10-10) is marked “undisclosed,” while the biggest disclosed amount is Telix Pharmaceuticals’ $600M on 2026-04-14. If underwriting or outreach needs consistent comparability, Telix’s disclosed size and Cell Bauhaus’s undisclosed amount are the main items that may require separate validation.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.